ArticleCytotechnology2025
Autoactivation of the HeLa 9903 test system during a full moon.
Article in Cytotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The HeLa 9903 cell line is used in the in vitro endocrine disruption assay (OECD 455). After treatment with an estrogen receptor agonist, the luminescence of these cells increases. However, some autoactivation of this test system may occur. The aim of this study was to try to explain the reason for the autoactivation of the HeLa 9903 cell line. Untreated cells were seeded on days with different moon phases and luminescence was measured the next day. Results from different moon phases were compared and statistically analyzed. An ELISA was also performed to check for the possible expression of 17β-estradiol. Statistical analysis revealed that the increase in luminescence in untreated cells was related to the phase of the moon. When the visibility of the moon was greater than approximately 87.7% (full moon), the likelihood of the cells autoactivating was greater. ELISA revealed that this change was not related to the production of 17β-estradiol by the cells (ligand-independent activation of the estrogen receptor). This is the first study to show a relationship between the phase of the moon and the activation of cells cultured in vitro. The results are important for planning the study using this test system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.